Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study Using Amide Proton Transfer Magnetic Resonance Imaging Distinguishing Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically Confirmed Glioma after completion of planned biopsy or resection.~   High grade glioma histologies:~  * Glioblastoma~  * High Grade or Malignant Glioma~  * Anaplastic Astrocytoma~  * Anaplastic Oligodendroglioma~  * Gliosarcoma~  * Mixture of any of the above histologies Low Grade Histologies~  * Astrocytoma~  * Grade II or low grade glioma~  * Oligodendroglioma~  * Mixtures of the above histologies~2. Plan to undergo external radiation treatment as part of therapy~3. No prior therapeutic cranial radiotherapy~4. Can safely perform clinically indicated MRI (no contraindications to MRI with Gadolinium) as determined by the standard Johns Hopkins Radiation Oncology screening procedures,~Exclusion Criteria:~1. Patients who cannot undergo MRIs.~2. Patients who are allergic to gadolinium based contrast agent~3. Patients who have cardiac pacemaker or other electronic or metal implant~4. Patients who have chronic kidney disease judged sufficient to exclude them from the clinically indicated contrast enhanced MRI.~5. Female patients who is pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- APT MRI (Type: EXPERIMENTAL): Participants will have the standard MRI of the brain that is performed for radiation planning for brain tumors.~1. Addition of the additional MRI sequences to the standard MRI before radiation therapy. This typically adds 10-15 minutes to the length of the scan.~2. An additional MRI scan to be scheduled during one of the final five radiation treatment days that would not otherwise occur. There will be no contrast injection as part of this second scan. This may typically take 40-45 minutes.~3. Collection of information about participants' tumor, including copies of their MRIs and later outcome of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).